Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Gainers

Blue Apron Holdings, Inc. (NASDAQ:APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.

OpGen, Inc. (NASDAQ:OPGN) shares jumped 109% to $0.4201 after the company requested to withdraw its registration statement on Form S-1.

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares gained 66.3% to $0.3343 after the company announced it signed a One Billion Dollar Master Collateral Transfer Agreement with Blacksheep Trust for the purpose and general use of monetization for a period of up to 15 years.

CF Acquisition Corp. VIII (NASDAQ:CFFE) gained 61% to $29.51.

Femasys Inc. (NASDAQ:FEMY) surged 48% to $2.2650 after HC Wainwright maintained a Buy rating on the stock and raised its price target from $5 to $13.

RVL Pharmaceuticals plc (NASDAQ:RVLP) shares climbed 35.7% to $0.1060.

SeaStar Medical Holding Corporation (NASDAQ:ICU) gained 35% to $0.2528 after the company announced it was granted Breakthrough Device Designation by the FDA for its Selective Cytopheretic Device for Cardiorenal Syndrome.

Structure Therapeutics Inc. (NASDAQ:GPCR) shares climbed 31.6% to $49.30 after the company announced results from its Phase 1b clinical study of oral GLP-1 receptor agonist GSBR-1290 and provided a program update.

T2 Biosystems, Inc. (NASDAQ:TTOO) rose 26.6% to $0.2258.

Starbox Group Holdings Ltd. (NASDAQ:STBX) surged 22.8% to $1.0252.

Capstone Green Energy Corporation (NASDAQ:CGRN) gained 20% to $0.60.

Evolve Transition Infrastructure LP (NYSE:SNMP) jumped 19% to $1.6312.

Velo3D, Inc. (NYSE:VLD) jumped 18.8% to $1.4850.

SAB Biotherapeutics, Inc. (NASDAQ:SABS) gained 17.1% to $0.6150.

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) gained 17% to $0.24. Brainstorm Cell Therapeutics recently announced the FDA Advisory Committee voted that NurOwn did not demonstrate substantial evidence of effectiveness for treatment of mild to moderate ALS.

Tritium DCFC Limited (NASDAQ:DCFC) gained 16% to $0.3598.

Better Therapeutics, Inc. (NASDAQ:BTTX) rose 13.2% to $0.3899. Better Therapeutics completed enrollment in real-world evidence program evaluating long-term effectiveness of AspyreRx in Type 2 Diabetes.

Editas Medicine, Inc. (NASDAQ:EDIT) shares rose 12% to $7.75. Stifel upgraded Editas Medicine from Hold to Buy and raised the price target from $9 to $17.

Century Aluminum Company (NASDAQ:CENX) gained 10% to $7.27.

FingerMotion, Inc. (NASDAQ:FNGR) gained 9.3% to $6.29.

Duolingo, Inc. (NASDAQ:DUOL) climbed 8.9% to $173.32 after UBS initiated coverage on the stock with a Buy rating and a $195 price target.

Customers Bancorp, Inc. (NYSE:CUBI) gained 8.2% to $35.01. Raymond James initiated coverage on Customers Bancorp with a Strong Buy rating and announced a price target of $60.

NIKE, Inc. (NYSE:NKE) shares climbed 7.3% to $96.22 after posting upbeat quarterly earnings.

Losers

The Glimpse Group, Inc. (NASDAQ:VRAR) shares dipped 42.5% to $1.87 after the company reported a wider FY23 loss.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) fell 41.4% to $3.4090 after the company announced a $23 million registered direct offering.

Color Star Technology Co., Ltd. (NASDAQ:ADD) shares declined 28% to $1.08.

Vaccinex, Inc. (NASDAQ:VCNX) fell 25.8% to $1.12 after the company reported pricing of $9.6 million public offering.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) dipped 23.8% to $0.5321 after the company reported pricing of $4.5 million public offering.

EBET, Inc. (NASDAQ:EBET) fell 23.5% to $0.0396 after the company announced a 1-for-30 reverse stock split.

Corcept Therapeutics Incorporated (NASDAQ:CORT) declined 21% to $26.07.

Portage Biotech Inc. (NASDAQ:PRTG) fell 18.4% to $1.8599 after announcing a $6 million registered direct offering.

Baudax Bio, Inc. (NASDAQ:BXRX) fell 16.2% to $0.3789. Baudax Bio shares gained over 50% on Thursday after the company announced it was granted orphan drug designation by the FDA for TI-168 for the treatment of Hemophilia A with inhibitors.

Lifezone Metals Limited (NYSE:LZM) declined 15.7% to $13.05.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) tumbled 15% to $13.29. JP Morgan maintained Syndax Pharmaceuticals with an Overweight and lowered the price target from $36 to $33.

WaveDancer, Inc. (NASDAQ:WAVD) fell 13% to $0.2350.

Nine Energy Service, Inc. (NYSE:NINE) fell 11.7% to $4.00.

Ascent Solar Technologies, Inc. (NASDAQ:ASTI) declined 11.6% to $1.82.

Opera Limited (NASDAQ:OPRA) fell 11.3% to $11.57 after the company announced the pricing of its underwritten secondary public offering of 6,876,506 ADSs to be sold by a pre-IPO shareholder at a public offering price of $12.25 per ADS.

Greenfire Resources Ltd. (NYSE:GFR) declined 9.8% to $4.9605.

Bionomics Limited (NASDAQ:BNOX) fell 8.3% to $3.09. Bionomics shares jumped 244% on Thursday after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks.

Badger Meter, Inc. (NYSE:BMI) fell 6.7% to $145.13. Northcoast Research downgraded Badger Meter from Neutral to Sell.

Now Read This: Bitcoin Tops $27,000 After PCE Data; Pepe Emerges As Top Gainer